▶ 調査レポート

関節内補充療法のグローバル市場(~2027):5回注入、単回注入、3回注入

• 英文タイトル:Viscosupplementation Market Research Report by Product, Source, Application, End-use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Viscosupplementation Market Research Report by Product, Source, Application, End-use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「関節内補充療法のグローバル市場(~2027):5回注入、単回注入、3回注入」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2305D050
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、221ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社は、世界の関節内補充療法市場規模が2021年に2,529.64百万ドル、2022年には2,678.74百万ドルに達し、更に年平均6.07%成長して2027年には3,602.76百万ドルまで拡大すると予測しています。当調査資料は、関節内補充療法の世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析(5回注入、単回注入、3回注入)、原料別分析(動物性、非動物性)、用途別分析(変形性手関節症、変形性股関節症、変形性膝関節症)、最終用途別分析(病院、整形外科クリニック/外来手術センター)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの構成でまとめております。また、当書には、AbbVie Inc.、Alcon Inc.、Anika Therapeutics, Inc.、Avanos Medical, Inc.、Bausch Health Companies Inc.、Bioventus LLC、Contipro A.S.、F. Hoffmann-La Roche AG、Ferring B.V.、Fidia Farmaceutici S.p.A.、Gentex Pharma, LLC、LG Life Sciences Ltd.などの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の関節内補充療法市場規模:製品別
- 5回注入タイプの市場規模
- 単回注入タイプの市場規模
- 3回注入タイプの市場規模
・世界の関節内補充療法市場規模:原料別
- 動物性関節内補充療法の市場規模
- 非動物性関節内補充療法の市場規模
・世界の関節内補充療法市場規模:用途別
- 変形性手関節症における市場規模
- 変形性股関節症における市場規模
- 変形性膝関節症における市場規模
・世界の関節内補充療法市場規模:最終用途別
- 病院における市場規模
- 整形外科クリニック/外来手術センターにおける市場規模
・世界の関節内補充療法市場規模:地域別
- 南北アメリカの関節内補充療法市場規模
アメリカの関節内補充療法市場規模
カナダの関節内補充療法市場規模
ブラジルの関節内補充療法市場規模
...
- アジア太平洋の関節内補充療法市場規模
日本の関節内補充療法市場規模
中国の関節内補充療法市場規模
インドの関節内補充療法市場規模
韓国の関節内補充療法市場規模
台湾の関節内補充療法市場規模
...
- ヨーロッパ/中東/アフリカの関節内補充療法市場規模
イギリスの関節内補充療法市場規模
ドイツの関節内補充療法市場規模
フランスの関節内補充療法市場規模
ロシアの関節内補充療法市場規模
...
- その他地域の関節内補充療法市場規模
・競争状況
・企業情報

The Global Viscosupplementation Market size was estimated at USD 2,529.64 million in 2021 and expected to reach USD 2,678.74 million in 2022, and is projected to grow at a CAGR 6.07% to reach USD 3,602.76 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Viscosupplementation to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Five Injection, Single Injection, and Three Injection.

Based on Source, the market was studied across Animal and Nonanimal.

Based on Application, the market was studied across Hand Osteoarthritis, Hip Osteoarthritis, and Knee Osteoarthritis.

Based on End-use, the market was studied across Hospitals and Orthopedic Clinics/Ambulatory Surgical Centers (ASCs).

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Delaware, Georgia, Illinois, Minnesota, New Hampshire, Pennsylvania, Tennessee, Vermont, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Viscosupplementation market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Viscosupplementation Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Viscosupplementation Market, including AbbVie Inc., Alcon Inc., Anika Therapeutics, Inc., Avanos Medical, Inc., Bausch Health Companies Inc., Bioventus LLC, Contipro A.S., F. Hoffmann-La Roche AG, Ferring B.V., Fidia Farmaceutici S.p.A., Gentex Pharma, LLC, LG Life Sciences Ltd., Lifecore Biomedical, LLC, Quimfa S.A., Regen Lab SA, Sanofi S.A., Seikagaku Corporation, Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zimmer Biomet.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Viscosupplementation Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Viscosupplementation Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Viscosupplementation Market?
4. What is the competitive strategic window for opportunities in the Global Viscosupplementation Market?
5. What are the technology trends and regulatory frameworks in the Global Viscosupplementation Market?
6. What is the market share of the leading vendors in the Global Viscosupplementation Market?
7. What modes and strategic moves are considered suitable for entering the Global Viscosupplementation Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing Need for Non-Surgical Treatment for Osteoarthritis
5.1.1.2. Rising Occurrence of Lifestyle-Induced Disorders with Changing Eating Habits
5.1.1.3. Surge in Geriatric Population and Obesity Globally
5.1.2. Restraints
5.1.2.1. Side Effects and High Cost of The Hyaluronic Acid-Based Treatment
5.1.3. Opportunities
5.1.3.1. Ongoing Advancements in the Development of Hyaluronic Acid-Based Therapies
5.1.3.2. Extending Role of Viscosupplementation in Patellar Chondropathy
5.1.4. Challenges
5.1.4.1. Strict Regulatory Mandates for Approval and Short Duration of Lubrication and Pain Relief
5.2. Cumulative Impact of COVID-19

6. Viscosupplementation Market, by Product
6.1. Introduction
6.2. Five Injection
6.3. Single Injection
6.4. Three Injection

7. Viscosupplementation Market, by Source
7.1. Introduction
7.2. Animal
7.3. Nonanimal

8. Viscosupplementation Market, by Application
8.1. Introduction
8.2. Hand Osteoarthritis
8.3. Hip Osteoarthritis
8.4. Knee Osteoarthritis

9. Viscosupplementation Market, by End-use
9.1. Introduction
9.2. Hospitals
9.3. Orthopedic Clinics/Ambulatory Surgical Centers (ASCs)

10. Americas Viscosupplementation Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Viscosupplementation Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Viscosupplementation Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Alcon Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Anika Therapeutics, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Avanos Medical, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bausch Health Companies Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bioventus LLC
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Contipro A.S.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. F. Hoffmann-La Roche AG
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Ferring B.V.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Fidia Farmaceutici S.p.A.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Gentex Pharma, LLC
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. LG Life Sciences Ltd.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Lifecore Biomedical, LLC
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Quimfa S.A.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Regen Lab SA
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Sanofi S.A.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Seikagaku Corporation
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Smith & Nephew PLC
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Teva Pharmaceutical Industries Ltd.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Viatris Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Zimmer Biomet
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing